

**Ministry of the Health of Ukraine
Kharkov National Medical University
Department of Clinical Pharmacology and Internal Medicine**

CLINICAL PHARMACOLOGY

**Working notebook
For the foreign students self-work
Specialty “Dentistry”
VI medical faculty**

Student's name

faculty _____ **group** _____

Kharkov

2017

Clinical pharmacology. Self-study guide for 5 year English medium students (speciality “Dentistry”) / document compilers L.R. Bobronnikova, I.I.Kniazkova, V.V. Zlatkina, V.D.

Nemtsova, Y.N. Shaposhnikova, I.A. Ilchenko, A.S. Shalimova – Kharkiv: Kharkiv national medical university, 2017. – 55 p.

Document compilers: L.R. Bobronnikova

I.I.Kniazkova
V.V.Zlatkina
V.D. Nemtsova
Y.N.Shaposhnikova
I.A.Ilchenko
A.S.Shalimova

Клінічна фармакологія. Робочий зошит для самостійної роботи іноземних студентів IV курсу стоматологічного факультету які вивчаються англійською мовою / Упоряд.:

Л.Р.Боброннікова І.І.Князькова, В.В.Златкіна, В.Д.Немцова

Ю.М.Шапошнікова, І.А.Ільченко, А.С.Шалімова. – Харків: ХНМУ, 2017. – 55 с.

Упорядники: Л.Р.Боброннікова

І.І.Князькова
В.В. Златкіна,
В.Д.Немцова
Ю.Н.Шапошнікова,
І.А.Ільченко
А.С.Шалімова

It is approved
on the meeting of Academic Council
of Kharkov national medical university
Protocol #_3_ from “_30_” August____2017

In order to improve the quality of learning material and students level of knowledge in preparation for the practical training on clinical pharmacology in extraclass time the manuals in the form of a workbook for IV year foreign students speciality “Dentistry”, who are trained in English, were developed.

Worksheet prepared in accordance with the program for clinical pharmacology according to the credit-modular system of training.

TABLE OF CONTENTS

Practical lesson N1	
Topic 1. Subject and tasks of clinical pharmacology. The main dispositions of pharmacokinetics and pharmacodynamics. Drugs interaction, types of side effects, complication of drug therapy.....	5
Topic 2. Clinico-pharmacological characteristics of drugs that affect vascular tone	
Practical lesson N2	
Topic 3. Clinico-pharmacological characteristics of antianginal and antiischemic medical agents	
Topic 4. Clinico-pharmacological characteristics of drugs affecting blood clotting (antiplatelet drugs, anticoagulants, fibrinolytics, coagulants).....	14
Practical lesson N3	
Topic 5. Clinico-pharmacological characteristics of antibacterial and antimicrobial medical agents.....	
Topic 6. Clinico-pharmacological characteristics of anti-inflammatory drugs (steroidal and non-steroidal).....	22
Practical lesson N4	
Topic 7. Clinico-pharmacological characteristics of local anesthetics and antiseptics.....	
Topic 8. Clinico-pharmacological characteristics of antiallergic medicines.....	32
Questions to final control.....	40
Notes.....	43
List of the drugs.....	45
A notification card for an adverse reaction (Medical Form No. 137 / o).....	50
Protocol of the Medicinal Products Efficacy and Safety Assessment	53

Practical lesson N1

Topic 1. Subject and tasks of clinical pharmacology. The main dispositions of pharmacokinetics and pharmacodynamics. Drugs interaction, types of side effects, complication of drug therapy.

Topic 2. Clinico-pharmacological characteristics of drugs that affect vascular tone

1 LEVEL. Answer briefly in writing form:

1. Give the definition of:

I. *Pharmacokinetics*– _____

1) Absorption - _____

2) Bioavailability – _____

3) Distribution - _____

4) Elimination(excretion)- _____

2. Basic Pharmacokinetic Parameters (describe):

3. Pharmacodynamics - _____

1) Drug-drug interactions - _____

2) Adverse Drug Effects - _____

4. Basic Pharmacodynamic Parameters (describe):

4. Evidence based medicine basic parameters (describe):

- Placebo _____

- Clinical randomized multicenter trial- _____

1) a prospective trial- _____

2) a retrospective (case-control)- _____

3) a double-blind trial- _____

5. Pharmacogenetic- _____

6. Give the definition of:

1). Interaction between drugs – _____

a) Synergistic effect - _____

b) Antagonism - _____

c) Pharmacological incompatibilities - _____

d) Competitive antagonists - _____

e) Uncompetitive antagonists - _____

f) Pure agonists - _____

g) Partial agonists - _____

2. The factors or conditions that predispose or favour the appearance of interactions:

g) Partial agonists – _____

h) Adverse drug reactions- _____

3. Absorption interactions include:

4. Transport and distribution interactions

5. Metabolism interactions include

6. Excretion interactions include

7. Classification of adverse drug reactions

a) Onset of event

1. _____
2. _____
3. _____

b) Severity of reaction:

1. _____
2. _____
3. _____
4. _____

c) Types of adverse drug reactions:

1. _____
2. _____
3. _____
4. _____
5. _____
6. _____

d) Types of allergic reactions

1. _____
2. _____
3. _____
4. _____

8. Give the definitions to the concepts:

Antihypertensive drugs - _____

Optimal blood pressure _____

Target blood pressure _____

Hypotension _____

Orthostatic hypotension - _____

9. Classification of antihypertensive drugs

10. The ACE inhibitors contraindications:

11. The Angiotensin II receptors agonists contraindications:

12. Calcium antagonists of the dihydropyridine group adverse effects:

13. Indications for the beta-blockers in hypertension

14. Classification of diuretics

15. Contraindications for the use of beta-blockers:

16.Specify the medication that can cause hypotension in a patient

17.Specify groups of drugs used to treat hypotension.

Amount of incorrect answers: _____. Mark for the 1 level: _____.

2 level. Perform tests for self-control (for each questions, only one correct answer).

1. Which one of the following routes of drug administration produces the most rapid absorption?

- A. Inhalation
- B. Intravenous
- C. Oral
- D. Rectal
- E. Sublingual

2. If a drug is highly bound to plasma proteins, it

- A. has a large volume of distribution
- B. has a high renal clearance
- C. is a likely candidate for drug interactions
- D. is most likely carried by alpha-glycoprotein
- E. is a quaternary ammonium salt

3. Most drugs gain entry to cells by

- A. passive diffusion with zero-order kinetics
- B. passive diffusion with first-order kinetics
- C. active transport with zero-order kinetics
- D. active transport with first-order kinetics
- E. passive diffusion through membrane pores

4. Which of the following is not a side effect of the cholinergic blocker (Atropine)?

- A. Decreased pulse
- B. Urinary retention
- C. Constipation
- D. Mydriasis
- E. Lethargy

5. A patient with hypertension has been administered one of antihypertensive drugs. Blood pressure dropped back to normal, but the patient has developed a persistent dry cough.

6.Which of the following drugs has such a side effect?

- A Enalapril maleate
- B Propranolol
- C Clonidine

D Furosemide

E Nifedipine

7. Which of the following is not a side effect of the Vasodilator (Nifedipine)?

A. Nausea

B. Flush appearance

C. Vertigo

D. Sexual dysfunction

E. Hypotension

8. One of the major indicator of drug elimination from the human body is:

A. Effective halfbeak

B. Volume of distribution

C. Bioavailability

D. Bioequivalence

E. Highest concentration in blood

6. Which of the following is not a side effect of the Dieuretics (Loop dieuretics)?

A. Alkalosis

B. Nausea

C. Hypotension

D. Potassium deficits

E. Weakness

7.A 74 y.o. patient has been suffering from hypertension for 20 years. He complains offrequent headache, dizziness, he takes enalapril. Objectively: accent of the SII above aorta, Ps- 68 bpm, rhythmic, P- 160/110 mm Hg. What group of hypotensive medications could be additionally prescribed under consideration of the patient's age?

A. Thiazide diuretics

B. Loop diuretics

C. beta-adrenoreceptor blockers

D. alphaadrenoreceptor blockers

E. E.Central sympatholytics

8.A 67-year-old female patient suffering from the essential hypertension suddenly at night developed headache, dyspnea that quickly progressed to asphyxia. Objectively: the patient is pale, with sweaty forehead, AP- 210/140 mm Hg, heart rate - 120/min, auscultation revealed solitary dry rales and moist rales in the lower parts. The shins are pastose. What kind of emergency aid would be the most efficient in this case?

A. Nitroglycerin and furosemide intravenously

B. Enalapril and furosemide intravenously

C. Digoxin and nitroglycerin intravenously

D. Labetalol and furosemide intravenously

E. Nitroglycerin intravenously and capoten internally

9.What drug may cause constipation in a patient undergoing combined therapy for arterial hypertension?

A. Verapamil

B. Furosemide

C. Trimetazidine

D. Panangin

E. Acetylsalicylic acid in small dosages

10. A patient suffering from arterial hypertension and chronic bronchitis suddenly presented with dry cough and dyspnea. Body temperature remained unchanged. It is known that the patient takes captopril. These symptoms can be explained by increased generation of:

A Bradyquinine

B Angiotensin-1

C Renin
D Aldosterone
E Natriuretic peptide

1. A B C D	3. A B C D	5. A B C D	7. A B C D	9. A B C D
2. A B C D	4. A B C D	6. A B C D	8. A B C D	10. A B C D

Amount of incorrect answers: _____. Mark for the 2 level: _____.

3 level. Please solved next clinical situational tasks and write your answer:

Situational task 1. In a patient weighing 70 kg, acetaminophen has a $V_d = 70$ L and $CL = 350$ mL/min.

Calculate the approximately the elimination half-life of the drug

Situational task 2. A 60-year-old patient has essential hypertension stage II, coronary disease, bronchial asthma. After pharmacotherapy correction the patient exhibited a bronchospastic attack, intensified dyspnea.

Question: What group of medical agents could provoked this complication?

Question: Which other side effects could be seen in this group?

Situational task 3. A 56-year-old patient suffering from essential hypertension was prescribed an inhibitor of angiotensin converting enzyme (ACE) and a potassium-sparing diuretic. **Such combination is:**

- A Unreasonable because it increases risk of hyperkalemia development
- B Reasonable because it decreases risk of hyperkalemia development
- C Reasonable because it potentiates hypotensive effect of ACE inhibitor
- D Unreasonable because it reduces hypotensive effect of ACE inhibitor
- E Unreasonable because it increases risk of orthostatic collapse development

Situational task 4. During the combined pharmacotherapy a patient with peptic ulcer presented with black-coloured feces.

Question: What drug might have caused such change?

Question: Which other side effects could be seen in this group?

Amount of incorrect answers: _____. Mark for the 3 level: _____.

4 level. Write prescriptions for medicines:

Medication	Prescriptions
1. Enalapril	Rp: D.t.d. S.
2. Nifedipine	Rp: D.t.d. S.
3. Torasemide	Rp: D.t.d. S.
4. Bisoprolol	Rp: D.t.d. S.
5. Losartan	Rp: D.t.d. S.

Amount of incorrect answers: _____. **Mark for the 4 level:** _____.

Overall mark for the class: _____ **Teacher Signature:** _____

Student signature: _____

Practical class N2

Topic 3. Clinico-pharmacological characteristics of antianginal and antiischemic medical agents

Topic 4. Clinico-pharmacological characteristics of drugs affecting blood clotting (antiplatelet drugs, anticoagulants, fibrinolytics, coagulants)

1 level. 1. Complete the teaching table (1-3)

Table 1

The pharmacological properties of antianginal medical agents

Group	BP	Systemic vascular resistance	Venous tone	Pulmonary artery pressure	Heart rate	AV-, SA- conduction	Stroke volume	Myocardial contractility	Oxygen demand	Blood flow		Motility of the gastrointestinal tract	Bronchial tone
										Coronary	Cerebral		
1. Organic nitrates													
Nitroglycerine													
Isosorbide dinitrate													
Isosorbide mononitrate													
2. β-blockers													
Non-selective β1, β2													
Selective β1													
3. Calcium antagonists													
Phenylalkylamines													
Dihydropyridines													
Benzothiazepines													
Biphenyl piperazines													
4. Inhibition of the funny channel													
Ivabradine													

Denote the effect availability: ↓ - decrease, 0 - no effect, ↑ - increase

Table 2

Indications for application of antianginal agents

Indication	nitrates	β -blockers	Calcium antagonists	ivabradine
------------	----------	-------------------	---------------------	------------

		Non-selective	Selective	Phenylalkylamines	Dihydropyridines	Benzothiazepines	Biphenyl piperazines	
Angina attacks prophylaxis								
Acute attack of angina pectoris								
Acute myocardial infarction								
Pulmonary edema								
Hypertension								
Cardiac arrhythmias: tachyarrhythmias								
Cardiac arrhythmias: bradyarrhythmias								
Cerebrovascular accident								

Indicate the effect availability: +, ++, -

Table 3

Adverse effects of antianginal agents

Side effect	Nitrates	β -blockers		Calcium antagonists			Ivabradine
	Nitroglycerine	Propranolol	Bisoprolol	Verapamil	Nifedipine		
Hypotension							
Orthostatic collapse							
Tachycardia							
Bradycardia							
Bronchospasm							
Heart failure							
Constipation, urinary retention							
Swelling of feet and ankles							
Headache, dizziness							
Flushing of skin							
Hypoglycemia							
Metgemoglobinemiya							
Withdrawal syndrome							
Tolerance							

Indicate the effect availability: +, ++, -

Answer briefly in writing form:

1. Classification of anticoagulants:

[illegible]

8.Indications for the antithrombotics prescription

9.Factors determining the effectiveness of antiplatelet therapy

10.New oral anticoagulants (NOA)

11.Classification of drugs that increase blood clotting.

The number of wrong answers: _____. Teacher's evaluation for the level 1 _____.

2 level. Perform tests for self-control (for each questions, only one correct answer)

1. 70 year old male with confirmed multi-vessel coronary vascular disease also suffers from COAD [chronic obstructive airway disease] and exertional angina. He is prescribed nifedipine for his angina, but shortly after beginning the medication complains of increased angina incidence. Choose an explanation:

- A. Nifedipine should not be used for angina.
- B. Nifedipine- a calcium channel blocker, causes significant vasodilation, hypotension and reflex cardiac stimulation result in increased anginal episodes
- C. Nifedipine in combination with propranolol, since propranolol would block reflex tachycardia due to nifedipine's vasodilatory effects.

2. Antianginal drug administered by inhalation:

- A. Isosorbide dinitrate
- B. Glyceryl trinitrate
- C. Amyl nitrite
- D. Isosorbide mononitrate

3. Symptoms associated with nitrates:

- A. Bradycardia
- B. Hypotension
- C. Headache

- D. Hypertension
 - E. B & C
- 4. Prinzmetal (variant) angina presents in a 25 year old female. Pharmacological management could include:**
- A. Diltiazem
 - B. Verapamil
 - C. Propranolol
 - D. Atenolol
 - E. A & B
- 5. Calcium channel blocker(s) most likely to affect myocardial contractility and AV conduction:**
- A. Diltiazem
 - B. Nifedipine
 - C. Nicardipine
 - D. Atenolol
 - E. Isosorbide dinitrate
- 6. What level of in diastolic blood pressure is prohibited to conduct thrombolytic therapy?**
- A. 90 mm Hg
 - B. 95 mm Hg
 - C. 100 mm Hg
 - D. 105 mm Hg
 - E. 110 mm Hg
- 7. A patient with a history of both angina and esophageal spasms is told by his physician that upon recurrence of pain, take a nitroglycerin tablet, sublingually and note what happens. When pain recurs, the patient takes the "nitro" and the pain goes away in about a minute. Reasonable analysis would suggest:**
- A. That the pain was due to myocardial oxygen insufficiency, relieved by the action of nitroglycerin on cardiac preload
 - B. That the pain is more likely due to esophageal spasm, because if it were due to the heart, relief would have taken longer
 - C. The test is inconclusive, since nitrates relax almost all smooth muscle terminating anginal symptoms or symptoms of esophageal spasm
- 8. Which of the following statements regarding enoxaparin is incorrect?**
- A. Subcutaneous injection is rapidly absorbed
 - B. Do not administer in case of severe renal failure
 - C. Can be used when body weight is above 150 kg
 - D. Has a high antithrombotic activity against Xa factor
 - E. Has a high antiaggregant activity
- 9. Which of the following does not refer to absolute contraindications to thrombolytic therapy?**
- A. Age over 70 years
 - B. First trimester of pregnancy
 - C. Severe diabetic retinopathy
 - D. Hemorrhagic diathesis
 - E. Peptic ulcer disease
- 10. Principal mechanism by which sublingual nitroglycerin terminates anginal episodes in patients with advanced atherosclerotic coronary vessel disease:**
- A. Coronary vasodilation
 - B. Decreased afterload
 - C. Decreased preload
 - D. Decreased heart rate
 - E. Decreased contractility

1. A B C D	3. A B C D	5. A B C D	7. A B C D	9. A B C D
2. A B C D	4. A B C D	6. A B C D	8. A B C D	10. A B C D

The number of wrong answers: _____. Teacher's evaluation for the level 2 _____.

3 level. Please solved next clinical situational tasks and write your answer:

Situational task 1. A 60-year-old man comes into the office complaining of chest pains that primarily occur in the early morning and do not appear to be associated with stress or exercise. Following coronary angiography and positive Ergonovine stress-test you determine that this patient has angina pectoris as a result of coronary artery spasm.

1. How would you treat the patient to alleviate the acute attacks when they occur ?

2. How would you treat chronically to prevent their reoccurrence?

Situational task 2. A 72-year-old woman was taken to the emergency room with attacks of intense heart pain and the presence of a transient myocardial infarction without ST elevation (NSTEMI). In the history such compressive pain in the chest during exercise appeared approximately 1-2 times a day. She underwent coronary angiography and 2 stents were installed in places of critical narrowing of the coronary vessels.

Concomitant drug therapy of the patient includes atorvastatin 20 mg daily, clopidogrel 75 mg daily, aspirin 100 mg daily, carvedilol 6.25 mg twice daily. After objective examination nitroglycerin in an inhaled form for episodic admission in angina attacks was also prescribed. Two weeks after discharge from the hospital, she came for a follow-up examination. When examined complains about episodes of intense headache, heartburn, general weakness

Question: 1. For which of the prescribed drugs are these side effects inherent? _____

Question 2. Can be in addition to this therapy prescribed verapamil and why?

Situational task 3. A 62-year-old male smoker with type 2 diabetes mellitus and hypertension presents with a 4-month history of exertional chest pain. Physical examination shows a blood pressure of 152/90 mm Hg, but is otherwise unremarkable. The ECG is normal, and laboratory tests show a fasting blood glucose value of 110 mg/dL, glycosylated hemoglobin 6.0%,

creatinine 1.1 mg/dL, total cholesterol 160, LDL 120, HDL 38, and triglycerides 147 mg/dL. He exercises for 8 minutes, experiences chest pain, and is found to have a 2-mm ST-segment depression in the inferolateral leads at the end of exercise.

Question 1. What 1) other tests should you do ?

Question 2. What strategies to control anginal symptoms would be most likely to be used?

Situational task 4. A 72-year-old female who presented to the emergency department with history of chest pain and non-ST-segment elevation myocardial infarction (NSTEMI). Her past medical history was significant for intermittent chest pain. She underwent cardiac catheterization with placement of 2 drug eluting stents.

Her medication list included atorvastatin 20mg daily, clopidogrel 75mg daily, aspirin 162mg daily, diltiazem 60mg four times a day. After examination she was started on ranolazine for symptomatic relief of NSTEMI with angina. She presented 2 days after discharge with 2 syncope episodes, dizziness, constipation, and abdominal pain. Brain MRI (magnetic resonance imaging) and blood works including liver enzymes, renal function, and electrolytes all were within normal limits.

1. For which drugs are typical these side effects?

2. What concomitant medical agents are forbidden to take together with ranolazine and why?

**The number of wrong answers: _____. Teacher's evaluation for the level 3 _____.
4 level. Write prescriptions for medicines:**

Medication	Prescriptions
1. Nitroglycerin	Rp: D.t.d. S.
2. Hydralazine	Rp: D.t.d.

	S.
3. <i>Verapamil</i>	Rp: D.t.d. S.
4. <i>Metoprolol</i>	Rp: D.t.d. S.
5. <i>Varfarin</i>	Rp: D.t.d. S.

The number of wrong answers: _____. Teacher's evaluation for the level 4 _____.

Overall teacher's evaluation for the class: _____ Signature of teacher: _____

Signature of student: _____

Practical lesson N3

Topic 5. Clinico-pharmacological characteristics of antibacterial and antimicrobial medical agents.

Topic 6. Clinico-pharmacological characteristics of anti-inflammatory drugs (steroidal and non-steroidal)

LEVEL 1. Answer briefly in writing form:

1. Give the definition of:

Antibacterial medications - _____

Minimum inhibitory concentration (MIC) - _____

The value of minimum inhibitory concentration for assigning antibacterial medications _____

Eradication _____

Postantibiotic effect _____

Basic requirements for the dosage regimen of antibacterial drugs _____

Drugs with a dose-dependent effect _____

Drugs with time-dependent effect _____

Glucocorticoids - _____

Cyclooxygenase (COX) - _____

2. Classification of NSAIDs

3. Clinical uses of NSAIDs

1. _____
2. _____
3. _____
4. _____

4. Adverse effects of NSAIDs

1) gastrointestinal effects: _____

2) renal effects: _____

3) _____

4) central symptoms: _____

5) allergic reactions: _____

5. Classification of glucocorticoids:

6. Mechanisms of glucocorticoid action :

a) Impact on the immune system:

b) Effect on water and electrolyte metabolism :

c) Effects on metabolism :

d) Impact on CVS Impact on the system of the hypothalamus -pituitary- adrenal Effects on blood:

7. Indications for glucocorticoids:

1. _____
2. _____
3. _____
4. _____
5. _____

13. Contraindication for glucocorticoids:

1. _____
2. _____
3. _____
4. _____
5. _____
6. _____

Complete the teaching table (1-3)

Table 1

Classification of antibacterial agents into bactericidal and bacteriostatic

Bactericidal	Bacteriostatic
1.	1.
2.	2.
3.	3.
4.	4.
	5.

Table 2

Classification of antibacterial agents according to mechanism of action

Mechanism of action	Antibacterial agent
Inhibition of cell wall synthesis	1. 2. 3. 4.
Inhibition of DNA gyrase	
Inhibition of RNA polymerase	
Inhibition of protein synthesis	1. 2. 3. 4.
Inhibition of folic acid metabolism	1. 2.

Table 3

Classes of Antibiotics and their Properties (summary of the types or classes of antibiotics and their properties including their spectrum and mode of action).

Chemical class	Examples	Spectrum (effective against)	Mode of action
<i>Example of filling</i>			
Beta-lactams (penicillins and cephalosporins)	Penicillin G, Cephalothin	Gram-positive bacteria	Inhibits steps in cell wall (peptidoglycan) synthesis and murein assembly
Semisynthetic beta-lactams			
Clavulanic Acid			
Monobactams			
Carboxypenems			
Aminoglycosides	Streptomycin		
	Gentamicin		

Glycopeptides	Vancomycin		
Lincomycins			
Macrolides			
Polypeptides	Polymyxin		
	Bacitracin		
Polyenes	Amphotericin		
	Nystatin		
Rifamycins	Rifampicin		
Tetracyclines	Tetracycline		
Semisynthetic tetracycline	Doxycycline		
Chloramphenicol	Chloramphenicol		
Quinolones	Nalidixic acid		
Fluoroquinolones	Ciprofloxacin		

Cephalosporins			
Growth factor analogs	Sulfanilamide, Gantrisin, Trimethoprim		
	Isoniazid (INH)		
	Para-aminosalicylic acid (PAS)		

The number of wrong answers: _____. Teacher's evaluation for the level 1 _____.

2 level. Perform tests for self-control (for each questions, only one correct answer)

1. Activity COX can be inhibited with the use of some medications. Which one has the irreversible inhibitory effect on this enzyme ?

- A. Norsulfazol
- W. Diclofenac sodium
- S. Sulfodimezyn
- D. Aspirin
- E. Tocopherol

2. Continious taking of a drug can result in osteoporosis, erosion of stomach mucous membrane, hypokaliemia, retention of sodium and water, reduced content of corticotropin in blood. Name this drug:

- A. Prednisolone
- B. Hydrochlorothiazide
- C. Digoxin
- D. Indometacin
- E. Reserpine

3. A 31 year old man complains about dryness, burning of tongue dorsum that appeared for about a week ago and is getting worse during eating stimulating food. Some time ago the patient had pneumonia. He spent two weeks at a hospital, was taking antibiotics. He doesn't take any drugs at the moment. Objectively: mucous membrane of oral cavity is hyperemic, dry and glossy. On the tongue dorsum and palate some grayish-white films are present that can be easily removed. Threads of saliva follow the spatula. What is the most probable diagnosis?

- A. Acute atrophic candidosis
- B. Chronic hyperplastic candidosis
- C. Chronic atrophic candidosis
- D. Drug-induced stomatitis

E. Acute pseudomembranous candidosis

4. Minimal duration of antibacterial treatment usually is:

- A. Not less than 1 day
- B. Not less than 5 days
- C. Not less than 10-14 days
- D. Not less than 3 weeks

5. A patient suffering from stomach ulcer has been treated with an antacid drug almagel. For acute bronchitis treatment he was prescribed the antibiotic methacycline. However within next 5 days the fever didn't fall, cough and sputum nature remained unchanged. A physician came to the conclusion that the drugs were incompatible. What type of drug incompatibility is the case?

- A. Pharmaceutic
- B. Pharmacodynamic
- C. Pharmacokinetic, absorption stage
- D. Direct antagonism
- E. Pharmacokinetic, biotransformation stage

6. An infectious patient manifests sensitization to penicillin. Which of the following antibiotics is the safest to be applied in this case?

- A. Ampicillin
- B. Erythromycin
- C. Oxacillin
- D. Amoxicillin
- E. Bicillin

7. A female patient in the first trimester of pregnancy has been diagnosed with acute pyelonephritis. What is the antibiotic drug of choice for treating this patient?

- A. Norfloxacin
- B. Amoxicillin
- C. Amikacin
- D. Chloramphenicol
- E. Gentamicin

8. A 9 y.o. child has been taking antibiotics on account of bronchopneumonia for a long time. There appeared pain and burning in the area of mucous membrane of his lips and tongue. Objectively: mucous membrane of lips and tongue has caseous and grey plaques that can be easily removed by a spatula leaving hyperemia foci on their spot. Microscopical examination of the plaques revealed mycelium. What is the most probable diagnosis?

- A. Candidous cheilitis
- B. Exfoliative cheilitis
- C. Leukoplakia
- D. Contactant allergic cheilitis
- E. Manganottis cheilitis

9. Patients with asthma who regularly takes prednisone pills and inhaled formoterol due to bronchopulmonary infection were assigned erythromycin, Bromhexine and theophylline. On the third day of treatment headache, palpitation, reduction in blood pressure, nausea and vomiting were developed. The toxic effect of which drug is associated with these symptoms?

- A. Theophylline
- B. Prednisone
- C. Erythromycin
- D. Formoterol
- E. Bromhexine

10. A 4 years old child is for the treatment of acute tonsillitis was administered an antibacterial drug. After 2 weeks after treatment there was the yellow color of the teeth,

which cannot be removed with toothpaste. Which antibiotic might have caused this complication?

- A. Azithromycin
- B. Metronidazole
- C. Tetracycline
- D. Ceftriaxone
- E. Amikacin

1. A B C D	3. A B C D	5. A B C D	7. A B C D	9. A B C D
2. A B C D	4. A B C D	6. A B C D	8. A B C D	10. A B C D

3 level. Please solved next clinical situational tasks and write your answer:

Situational task 1. While on holiday in Spain, a 62-year-old man develops a cough, fever and breathlessness at rest. He is told that his chest x-ray confirms that he has right side segmental pneumonia. He is started on a seven-day course of oral antibiotics by a local physician and stays in his hotel for the remainder of his ten-day holiday. When he returns home, he is reviewed by his own GP who notices that he looks pale and sallow and is still breathless on exertion, but his chest examination no longer reveals any signs of pneumonia. A full blood count reveals a haemoglobin level of 6.7 g/dL (previously normal), normal white blood count and platelets, and a reticulocyte count of 4.1%.

Question: What other tests should you do and what antibiotics would be most likely to cause this clinical scenario?

Situational task 2. A 53-year-old woman who has been treated for rheumatoid arthritis for a long time complains about arterial pressure rise, gastric pain, heartburn.

Question: What preparation has she taken?

Question: What other side effects this drug can occur?

Situational task 3. A 53-year-old woman who has been treated for rheumatoid arthritis for a long time complains about arterial pressure rise, gastric pain, heartburn.

Question: What preparation has she taken?

Question: What other side effects this drug can occur?

Situational task 4. A baby, aged 8 months, is examined and a diagnosis of atypical community-acquired pneumonia of chlamydial etiology is made.

Question: What is the optimum alternative of antibiotics therapy in this case?

The number of wrong answers: _____. Teacher's evaluation for the level 3 _____.

4 level. Write prescriptions for medicines:

Medication	Prescriptions
<i>Gatifloxacin</i>	Rp: D.t.d. S.
<i>Co-amoxiclav</i> (<i>amoxicillin/clavulanic acid</i>)	Rp: D.t.d. S.
<i>Azithromycin</i>	Rp: D.t.d. S.
<i>Ceftriaxone</i>	Rp: D.t.d. S.
<i>Paracetamol</i>	Rp: D.t.d. S.
<i>Ibuprofen</i>	Rp: D.t.d. S
<i>Prednisone (in tablets)</i>	Rp: D.t.d. S

The number of wrong answers: _____. **Teacher's evaluation for the level 4 _____.**

Overall teacher's evaluation for the class: _____

Signature of teacher: _____

Signature of student: _____

Practical lesson N4

Topic 7. Clinico-pharmacological characteristics of local anesthetics and antiseptics
Topic 8. Clinico-pharmacological characteristics of antiallergic drugs.

1 LEVEL. Answer briefly in writing form

1. Give the definitions to terms:

1) Antigen – _____

2) Antibody – _____

3) *Target cells* – _____

4) *Antigen presenting cells* – _____

5) *Phagocytic cells* – _____

6) *Mediator cells* – _____

7) Atopy – _____

2. The aim of antiallergic drugs pharmacotherapy is:

3. Classification of Mast Cell Stabilizers:

4. Mechanism of Mast Cell Stabilizers Action:

<hr/> <hr/> <hr/> <hr/>
5. Mechanismal Classification of Leukotriene Modifiers? <hr/> <hr/> <hr/> <hr/> <hr/> <hr/> <hr/>
5. Pharmacological Actions of Leukotriene Modifiers <hr/> <hr/> <hr/> <hr/> <hr/> <hr/> <hr/>
6. Classification of H₁-antihistamines <hr/> <hr/> <hr/> <hr/> <hr/> <hr/> <hr/> <hr/>
7. Mechanism of H₁-antihistamines Action <hr/> <hr/> <hr/> <hr/> <hr/> <hr/> <hr/>
8. Adverse drug reactions of H₁-antihistamines <hr/>

9. Clinical use of H₁-antihistamines

10. Classification of local anesthetics

11. Local anesthetics mechanism of action

12. Factors affect the reactions of local anesthetics

13. The local adverse effects of local anesthetic agents include:

14. The General adverse effects of local anesthetic agents include:

15. Groups of antiseptics used in dental practice (with examples of the drugs):

16. Indications for antiseptics in dental practice:

Amount of incorrect answers: _____. Mark for the 1 level: _____.

2 level. Perform tests for self-control (for each question, only one correct answer)

1. All of the following drugs are effective for allergy Type 1, except:

- A. Adrenaline
- B. Aminophylline.
- C. Acetylsalicylic acid.
- D. Glucocorticoids.
- E. Diphenhydramine.

2. For urticaria could be used:

- A. antihistamines
- B. Antibiotics
- C. Diuretics
- D. antiplatelets
- E. vasodilators

3. A student came to see a doctor and asked to administer him a drug for treatment of allergic rhinitis that occurs in the period of linden flowering. What drug may be used?

- A. Loratadine
- B. Noradrenaline hydrotartrate
- C. Propanolol
- D. Ambroxol
- E. Losartan

4. A 45-year-old woman suffers from allergic seasonal coryza caused by the ambrosia blossoming. What medicine from the stabilizer of the adipose cells group can be used for prevention of this disease?

- A. Diazoline
- B. Ketotifen
- C. Phencarol
- D. Tavegil
- E. Dimedrol

5. Most of the daily dose of prednisolone should be administered

- A. in the evening
- B. in the afternoon
- C. in the morning
- D. at night
- E. Any time

6. A 25-year-old woman with red and itchy eczematoid dermatitis visits your office. She had a dental procedure one day earlier with administration of a local anesthetic. There were no other findings, although she indicated that she had a history of allergic reactions. Which of the following drugs is most likely involved?

- A. Procaine
- B. Cocaine
- C. Lidocaine
- D. Bupivacaine
- E. Etidocaine

7. In the treatment of anaphylactic shock are used

- A. corvalol, nitroglycerin
- B. atropine, menadione
- C. dibazol, pentamin
- D. adrenaline, prednisolone
- E. morphine, nitroglycerin

8. Your medical student patient suffers from troublesome allergic rhinitis due to pollen, and you want to prescribe a drug for her that is least likely to cause sedation. Your best choice would be

- A. betamethasone
- B. cimetidine

- C. hydroxyzine
- D. loratadine
- E. metoclopramide

9. Before the infiltration anaesthesia a patient had been tested for sensitivity to novocaine. The reaction turned out to be positive. Which of the below listed drugs can be used for anaesthetization in this case?

- A. Trimecaine
- B. Procainamide hydrochloride
- C. Anesthezin
- D. Tetracaine
- E. Lidocaine

10. A 22-year-old patient is afraid of pain from conduction anaesthesia. A dentist decided that this anaesthesia should be preceded by applicational anaesthesia of mucous membrane on the spot of injection. What drug should be used for this purpose?

- A. 1% synthomycin ointment
- B. 5% lidocaine ointment
- C. 5% oxacillin ointment
- D. 3% sinaflan ointment
- E. 3% doxycyclin ointment

1. A B CDE	3. A B CDE	5. A B CDE	7. A B CDE	9. A B CDE
2. A B CDE	4. A B CDE	6. A B C D E	8. A B C D E	10. A B C D E

Amount of incorrect answers: _____. Mark for the 2 level: _____.

3 level. Solve the clinical situational tasks:

Situational task 1. A 16-year-old adolescent was vaccinated with DTP. In eight days there was stiffness and pain in the joints, subfebrile temperature, urticarial skin eruption, enlargement of inguinal, cervical lymph nodes and spleen.

Question: What kind of allergic reaction is observed?

Question: What treatment have to be prescribed?

Situational task 2. 32-year-old man visits a physician with complaints of severe itching, blisters all over his body. The condition relates to the use of fish. All symptoms present 2 days. Loratadine was prescribed.

Question: What side effects may occur in this case?

Situational task 3. For prophylaxy allergen-induced bronchospasm 27-years old woman was prescribed Ketotifen.

Question:What mechanisms of action of this drug make it useful in such cases?

Situational task 4. 15 minutes after the second vaccination with DTP vaccine a 4-month-old boy exhibited the symptoms of Quincke's edema.

Question: What medication should be given for emergency aid?

Question:What is the mechanism of action of this drug in this case?

Situational task 5. During local anesthetization (with 2 ml of 10% solution of lidocaine) a 9 year old girl cried out, lost consciousness, there appeared generalized convulsions. Objectively: the child's skin is pale and cyanotic. It is impossible to feel the pulse because of convulsions.

Question:What is your provisional diagnosis?

Question:What medication should be given for emergency aid?

Situational task 6. A patient got an injection of 0,25% novocaine solution for the purpose of anaesthetization. Suddenly the patient has presented with red spots, intense sweating, tachycardia, edema of nasal mucous membrane, bronchospasm,.

Question: What is the cause of this complication?

Amount of incorrect answers: _____. **Mark for the 3 level:** _____.

4 level. Prescribe the recipes:

Medication	Prescriptions
1. Loratadine	Rp: D.t.d.

	S.
2. Disodium Cromoglycate	Rp: D.t.d. S.
3. Ketotifen	Rp: D.t.d. S.
4. Lidocaine	Rp: D.t.d. S.
5. Bupivacaine	Rp: D.t.d. S.
6. Myramistin	Rp: D.t.d. S.

Amount of incorrect answers: _____. **Mark for the 4 level:** _____.

Overall mark for the class: _____

Teacher Signature: _____

Student signature: _____

APPROXIMATE LIST OF QUESTIONS TO FINAL CONTROL

1. Classification of lipid-lowering drugs.
2. Mechanism of action, pharmacokinetics and pharmacodynamics, indications and contraindications for statins.
3. Mechanism of action, pharmacokinetics and pharmacodynamics, indications and contraindications for fibrates administration.
4. Omega 3 - fatty acids. The mechanism of action. Features of the application.
5. Classification of dyslipidemia. Differentiated approach to the use of lipid-lowering medications.
6. Group of medicines related to the anti-ischemic and antianginal drugs.
7. Mechanism of action, pharmacological effects, indications and contraindications to organic nitrates administration.
8. Mechanism of action, pharmacokinetics and pharmacodynamics, indications and contraindications to beta - blockers.
9. Mechanism of action, pharmacokinetics and pharmacodynamics, indications and contraindications to calcium channel blockers.
10. Classification of calcium channel blockers. Peculiarities of administration. Dosage.
11. Classification of beta-blockers. Peculiarities of administration. Dosage.
12. Antiplatelet drugs. Classification. Mechanisms of action. Methods of administration.
13. Thrombolytic agents. Indications and contraindications for thrombolysis. Schemes of administration.
14. Anticoagulants. Classification. Mechanisms of action. Side effects.
15. Classification of antihypertensive drugs.
16. Differentiated approach to antihypertensive therapy with concomitant diseases (diabetes, asthma, pregnancy, old age, pheochromocytoma, etc.).
17. The mechanism of antihypertensive action, pharmacological effects, side effects when prescribing calcium antagonists dosage.
18. The mechanism of antihypertensive action, pharmacological effects, side effects when prescribing beta -blockers. Dosage.
19. The mechanism of antihypertensive actions, pharmacological effects, indications and contraindications, side effects when prescribing angiotensin-converting enzyme inhibitor. Dosage.
20. The mechanism of antihypertensive action, pharmacological effects, indications and contraindications, side effects when prescribing angiotensin II receptor antagonists. Dosage.
21. Principles of combined use of antihypertensive drugs.
22. Classification of antiarrhythmic medicines.
23. Differentiated approach to the administration of antiarrhythmic medications.
24. Classification of cardiac glycosides. Dosage.
25. Cardiac effects of cardiac glycosides (digoxin).
26. Indications for cardiac glycosides.
27. Clinical and ECG signs of cardiac glycosides intoxication.
28. Non-glycoside inotropic agents. Indications for use.
29. Classification of diuretics.
30. Mechanism of action, pharmacokinetics and pharmacodynamics, indications and contraindications for loop diuretics.
31. Mechanism of action, pharmacokinetics and pharmacodynamics, indications and contraindications for the purpose of thiazide and to thiazides similar agents. Dosage.
32. The mechanism of action and pharmacological effects of potassium sparing diuretics. Indications and contraindications for use. Dosage.
33. A differentiated approach to the choice of diuretic agents, depending on the presence of comorbidities (effects on lipid and carbohydrate metabolism).
34. Classification of medical agents affecting the bronchial patency.

35. Mechanism of action, pharmacokinetics and pharmacodynamics, indications and contraindications for β_2 agonists administration, short-acting β_2 agonists. Dosage.
36. Mechanism of action, pharmacokinetics and pharmacodynamics, indications and contraindications for β_2 agonists. Long-acting β_2 agonists. Dosage.
37. Methylxanthines, mechanism of action, pharmacological effects, side effects. Dosage.
38. Glucocorticoids. Advantages of inhaled forms. Different dosing regimens.
39. Systemic adverse events occurring with prolonged use of glucocorticoids.
40. Withdrawal effects of glucocorticosteroids.
41. Antitussive agents. Mechanisms of action. Dosing regimens.
42. Drugs interaction.
43. Types of side effects.
44. Classification of NSAIDs.
45. Mechanisms of action, pharmacological properties of NSAIDs.
46. Indications and contraindications. Side effects of NSAIDs.
47. Regime of NSAIDs dosing.
48. The most frequent mistakes in antimicrobial drugs prescribing.
49. Allergic reactions to administration of antibacterial agents . Clinical implications.
50. Classification. The spectrum of activity. Mechanism of action . Features of the penicillins application. Dosage.
51. Classification. The spectrum of activity. Mechanism of action . Features the cephalosporins use. Dosage.
52. Classification. The spectrum of activity. Mechanism of action . The carbapenems application features. Dosage.
53. Classification. The spectrum of activity. Mechanism of action . Features of aminoglycosides use. Dosage.
54. Classification. The spectrum of activity. Mechanism of action. Features the fluoroquinolones use. Dosage.
55. Classification. The spectrum of activity. Mechanism of action. The macrolides application features. Dosage.
56. Medications that stimulate motility of the gastrointestinal tract. Classification.
57. Mechanism of action, pharmacokinetics and pharmacodynamics , indications and contraindications for the dopamine receptors selective blockers. Dosage.
58. Clinical and pharmacological characteristics of drugs which inhibit the digestive tract motility - loperamide. Dosage.
59. Medical agents with spasmolytic activity, mechanisms of action , pharmacological properties, indications , contraindications, dosage.
60. Medical agents with anti-secretory activity.
61. Classification, mechanism of action, pharmacokinetics and pharmacodynamics, indications and contraindications for the purpose of proton pump inhibitors. Dosage.
62. Classification, mechanism of action, pharmacokinetics and pharmacodynamics, indications and contraindications for the use of H₂-histamine receptor blockers. Dosage.
63. Antacids mechanism of action. Pharmacological properties. Dosage.
64. Cytoprotectors . Pharmacological features. Dosage.
65. Hepatoprotectors . Classification. Mechanism of action, pharmacokinetics and pharmacodynamics , indications and contraindications for use. Dosage.
66. Pancreatic enzymes. Pharmacological features. Indications for use. Side effects .Dosage .
67. Complications of drug therapy.
68. Classification, mechanism of action, pharmacokinetic and pharmacodynamic , indications and contraindications for antiallergic drugs. Dosage .

Notes

Notes

**LIST OF ALL MEDICATIONS WHICH STUDENTS OF MEDICAL AND
DENTISTRY FACULTIES MUST KNOW**

ANTIBACTERIAL AGENTS

- | | |
|-------------------------------|----------------------------|
| 1. Benzylpenicillin -sodium | 11. Amoxicillin |
| 2. Oxacillin – sodium | 12. Clavulanicacid |
| 3. Ampicillin – sodium | 13. Rovamicin |
| 4. Carbenicillin | 14. Diflucan / Fluconazole |
| 5. Clarithromycin | 15. Levofloxacin |
| 6. Gentamycin sulfate | 16. Gatifloxacin |
| 7. Tetracycline hydrochloride | 17. Moxifloxacin |
| 8. Doxycycline hydrochloride | |
| 9. Erythromycin | |
| 10. Azithromycin | |

ANTIVIRAL AGENTS

- | | |
|---------------------------------|----------------|
| 1. Interferon-alpha | 3. Ribavirin |
| 2. Interferon-alpha (pegylated) | 4. Lamivudine |
| | 5. Rimantadine |

ANTIPARASITICAGENTS

- | | |
|--------------------|-------------------------|
| 1. Quinine sulfate | 4. Vermox (Mebendazole) |
| 2. Primaquine | 5. Pyrantel |
| 3. Albendazole | |

NONSTEROID ANTI-INFLAMMATORY AGENTS

- | | |
|------------------------|-------------|
| • Acetylsalicylic acid | • Nimesulid |
| • Indometacin | • Meloxicam |
| • Diclofenac sodium | • Celecoxib |
| • Ibuprofen | |

GLUCOCORTICOIDS

- | | |
|---------------------|----------------------|
| • Cortisone Acetate | • Dexamethasone |
| • Prednisolone | • Budesonide |
| • Triamcinolone | • Methylprednisolone |

IMMUNOMODULATORS AND ANTIRHEUMATIC DRUGS

- | | |
|--------------------------------------|--------------------------|
| 1. Plaquenil
(Hydroxychloroquine) | 3. Azathioprine (Imuran) |
| 2. Levamisole | 4. Chlorbutin |
| | 5. D-penicillamine |

CARDIAC GLYCOSIDE

- | | |
|--------------|-----------------|
| 1. Digoxin | 2. Strophanthin |
| 2. Digitoxin | 3. Corglycone |

PERIPHERAL VASODILATOR

- | | |
|-------------------------|------------------------------|
| 1. Nitroglycerine | 4. Isosorbide Dinitrate |
| 2. Molsidomine | 5. Isosorbide -5-Mononitrate |
| 3. Nitroprusside Sodium | |

ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS AND ANGIOTENSIN II RECEPTOR ANTAGONISTS

- | | |
|----------------------|-----------------|
| 2. Captopril | 7. Quinapril |
| 3. Enalapril maleate | 8. Losartan |
| 4. Lisinopril | 9. Irbesartan |
| 5. Perindopril | 10. Olmesartan |
| 6. Ramipril | 11. Telmisartan |
| | 12. Valsartan |

CALCIUM CHANNEL-BLOCKING AGENT

- | | |
|---------------|------------------|
| 2. Verapamil | 5. Amlodipine |
| 3. Diltiazem | 6. Nimodipine |
| 4. Nifedipine | 7. Lercanidipine |

HYPOLIPIDEMIC AGENTS

- | | |
|-----------------|----------------|
| 3. Simvastatin | 6. Lovastatin |
| 4. Atorvastatin | 7. Fenofibrate |
| 5. Rosuvastatin | |

MEDICINES WHICH TAKE ACTION ON ADRENERGIC SYSTEM

- | | |
|-----------------|----------------|
| 1. Phentolamine | 8. Doxazosin |
| 2. Pyroxan | 9. Propranolol |
| 3. Moxonidine | 10. Metoprolol |

- | | |
|---------------|----------------|
| 4. Methyldopa | 11. Bisoprolol |
| 5. Dopamine | 12. Nibivolol |
| 6. Dobutamine | 13. Carvedilol |
| 7. Prazosin | |

DIURETICS

- | | |
|------------------------|------------------------|
| 1. Hydrochlorothiazide | 6. Ethacrynic acid |
| 2. Indapamide | 7. Eplerenone (inspra) |
| 3. Clopamide | 8. Diamide |
| 4. Furosemide | 9. Spironolactone |
| 5. Torsemide | 10. Mannitol |

ANTIARRHYTHMIC DRUG

- | | |
|----------------|------------------|
| 1. Amiodarone | 3. Propafenone |
| 2. Dronedarone | 4. Novocainamide |

MEDICAL AGENTS FOR THE TREATMENT OF AIRWAY CONDUCTANCE ABNORMALITIES

- | | |
|----------------------------|----------------------------|
| 4. Orciprenaline (alupent) | 8. Ephedrine hydrochloride |
| 5. Fenoterol | 9. Cromoglycate Sodium |
| 6. Izadrine hydrochloride | 10. Nedocromil Sodium |
| 7. Tiotropium bromide | 11. Ketotifen |

MEDICAL AGENTS FOR THE TREATMENT OF DIGESTIVE SYSTEM DISEASES

- | | |
|--------------------------|----------------------|
| 4. Almagel | 18. Loperamide |
| 5. Bismuth subcitrate | 19. Omeprazole |
| 6. Famotidine | 20. Lansoprazole |
| 7. Alachole | 21. Rabeprazole |
| 8. Flamine | 22. Pantoprazole |
| 9. Cholestyramine | 23. Esomeprazole |
| 10. Cholestyramine | 24. Legalon |
| 11. Ursodeoxycholic acid | 25. Silibor |
| 12. Festale | 26. Bifidum-bacterin |
| 13. Pancreatine | 27. Linex |
| 14. Digestal | 28. Mebeverine |

- | | |
|------------------------|-----------------------|
| 15. Plantaglucide | 29. Metoclopramide |
| 16. Ademethionin | 30. Domperidone |
| 17. Sodium picosulfate | 31. Prifinium bromide |
| | 32. Ondasetron |

TISSUE METABOLISM ACTIVATORS

- | | |
|--------------|------------------|
| 3 Solcoseryl | 5 Pentoxifylline |
| 4 Aktovegin | 6 Thiotriazoline |

ANTICOAGULANT, ANTITHROMBOTIC, AND THROMBOLYTIC AGENTS

- | | |
|---------------------|----------------|
| 3 Ethamsylate | 8 Alteplase |
| 4 Vikasol | 9 Heparin |
| 5 Aminocaproic acid | 10 Nadroparin |
| 6 Ticlopidine | 11 Enoxaparin |
| 7 Streptokinase | 12 Fraxiparine |
| | 13 Fondaparin |

MEDICINES WHICH USED FOR THE TREATMENT FOR HEMOBLASTOSIS AND ANOTHER MALIGNANT TUMORS

- | | |
|-------------------|-------------------------------|
| 1. Methotrexate | 5. Phosphazine |
| 2. Cyclophosphane | 6. Procarbazine hydrochloride |
| 3. Mercaptopurine | 7. Myelosan |
| 4. Fluorouracil | 8. Rubomycine hydrochloride |

MEDICATIONS FOR THE TREATMENT FOR PROFESSIONAL POISONING

- | | |
|-----------------|-----------------------|
| 1. Alloxim | 4. Cuprenyl |
| 2. Dipiroxim | 5. Sodium thiosulfate |
| 3. Isonitrozine | 6. Pentacin |

READING LIST FOR LEARNING:

1. Goodman & Gilman's The Pharmacological Basis of Therapeutics / Laurence L. Brunton, Keith L. Parker, Donald K. Blumenthal, Iain L.O. Buxton / 11th edition/2007
2. Basic & Clinical Pharmacology / Bertram G. Katzung / 10th edition / 2006.
3. Katzung & Trevor's Pharmacology: Examination & Board Review / Trevor A.J., Katzung B.G., & Masters S.B. / 7th edition / 2005
4. USMLE Road Map: Pharmacology / Katzung B.G., Trevor A.J. / 2nd edition / 2006
5. База даних тестового контролю МОЗ України – Київ, 2013
6. Drug Facts and Comparisons. 2001 ed. St. Louis: Facts and Comparisons/ .- 2000.
7. Middleton, Elliott, Jr., et al., eds. Allergy: Principles and Practice / 5th ed. -St. Louis: Mosby.-Year Book.- 1998. 2v

CARD-NOTIFICATION FOR THE ADVERSE REACTION (AR) and/or lack of efficacy (LE) of the medical agent (MA) during its medical use	MEDICAL DOCUMENTATION Form No. 137 / o
--	---

I. GENERAL INFORMATION

1. Patient's initials	2. Number of history case/ source documentation	3. Date of birth			4. Sex	5. Consequence of AR/LO				
		day	month	year		<input type="checkbox"/> recovery	<input type="checkbox"/> recovery with sequelae			
						<input type="checkbox"/> recovers	<input type="checkbox"/> death not from AR			
						<input type="checkbox"/> without changes	<input type="checkbox"/> death probably from AR			
						<input type="checkbox"/> unknown	<input type="checkbox"/> death from AR			
6. Onset of AR/LO (date, time) /___/___/___/, /___/___/		7. End of AR (date, time) /___/___/___/, /___/___/			9. Category of AR/LO					
8. Description of the AR / Specification of the LO of the MA (including laboratory and instrumental research data, which relate to AR)						<input type="checkbox"/> patient's death /___/___/___/				
						<input type="checkbox"/> threat to life				
						<input type="checkbox"/> hospitalisation				
						<input type="checkbox"/> prolongation of hospitalization				
						<input type="checkbox"/> long-term disability, disability				
						<input type="checkbox"/> birth defects				
						<input type="checkbox"/> another important medical event				
						<input type="checkbox"/> none of the above				

II. INFORMATION ABOUT SUSPICIOUS medical agent (SMA), MANUFACTURER of SMA (for vaccines additionally see the reverse side of the map)

10. SMA (trade name, drug form)	11. Manufacturer, country				12. Serial number
13. Indications (indicate code of ICD-10, if possible)	14. Single dose	15. Multiplicity of intake	16. Way of administration	17. Beginning of SMA therapy	18. End of SMA therapy
				/___/___/___/	/___/___/___/

III. INFORMATION ON RELATED MEDICINES (except used for correction the results of AR)

19. Concomitant MA (trade name, drug form, manufacturer)	20. Indications (indicate code of ICD-10, if possible)	21. Single dose	22. Multiplicity of intake	23. Way of administration	24. Beginning of therapy	25. End of therapy
26. Other important information (diagnosis, allergy, pregnancy with the indication of the term, etc.)						

V. RESOURCES OF CORRECTION

<input type="checkbox"/> Withdraw of SMA Was the withdrawal of the SMA accompanied by the disappearance of the AR? <input type="checkbox"/> yes <input type="checkbox"/> no
<input type="checkbox"/> Reassignment of the SMA Was there a renewal of the AR after the reappointment of the SMA? <input type="checkbox"/> yes <input type="checkbox"/> no
<input type="checkbox"/> Change in the dosage regime of the SMA (decrease/ increase, indicate how much): Has the renewal of the AR/LO been marked after the change in the SMA dose regime? <input type="checkbox"/> yes <input type="checkbox"/> no
<input type="checkbox"/> Correction of AR/LO wasn't made
<input type="checkbox"/> Medicamental therapy AR/LO (indicate MA, dose regimen, duration of the indication):

**V. CAUSAL-INVESTIGATORY RELATIONS BETWEEN CLINICAL MANIFESTATIONS OF AR
AND SMA**

<input type="checkbox"/> certain	<input type="checkbox"/> probable	<input type="checkbox"/> possible	<input type="checkbox"/> uncertain	<input type="checkbox"/> not defined	<input type="checkbox"/> not classified
----------------------------------	-----------------------------------	-----------------------------------	------------------------------------	--------------------------------------	---

VI. INFORMATION ABOUT THE COMMUNICATOR

27. FULL NAME OF CONTACT PERSON, tel/fax, email	28. Notification was given by	29. Name and location of the institution or applicant		
	<input type="checkbox"/> physician <input type="checkbox"/> pharmacist <input type="checkbox"/> pharmacist <input type="checkbox"/> nurse <input type="checkbox"/> paramedic <input type="checkbox"/> obstetrician <input type="checkbox"/> the applicant			
30. Source of notification (p. 30-32 only for communicator)	31. Notification number assigned by the applicant	32. Date of receiving by the applicant	33. Type of notification	34. Date of completion
<input type="checkbox"/> physician <input type="checkbox"/> patient <input type="checkbox"/> investigation <input type="checkbox"/> literature <input type="checkbox"/> other			<input type="checkbox"/> primary <input type="checkbox"/> current <input type="checkbox"/> final	
The notification is filled in and provided at the GI "State Expert Center of the Ministry of Health of Ukraine", Department of Post-Registration Supervision, Ave. Ushinskogo, 40, Kiev, 03151; tel / fax: +38 044 4984358; e-mail: vigilance@dec.gov.ua; The electronic form of notification is available at http://www.dec.gov.ua/				

IIa. ADDITIONAL INFORMATION IN THE EVENT OF SUCCESSIVE ADVERSE REACTION TO VACCINES OR TUBERCULOSIS ALLERGENS

Category of immunization or tuberculin diagnostics		Category of adverse event after immunization or tuberculin diagnostics		
<input type="checkbox"/> large-scale campaign <input type="checkbox"/> inoculation by age <input type="checkbox"/> at school <input type="checkbox"/> medical office for travelers <input type="checkbox"/> carrying out tuberculin diagnostics <input type="checkbox"/> other		<input type="checkbox"/> response to a vaccine <input type="checkbox"/> programme mistake <input type="checkbox"/> coincidence in time <input type="checkbox"/> reaction due to injection / fear of injection <input type="checkbox"/> unknown		
Dose number (for vaccine)	Place of the vaccine introduction/ tuberculosis allergen		Way of vaccine introduction/ tuberculosis allergen	
<input type="checkbox"/> the first <input type="checkbox"/> the fourth <input type="checkbox"/> the second <input type="checkbox"/> the fifth <input type="checkbox"/> the third <input type="checkbox"/> >the fifth	<input type="checkbox"/> left shoulder <input type="checkbox"/> right shoulder <input type="checkbox"/> shoulder (without specifying.) <input type="checkbox"/> left hip <input type="checkbox"/> right hip	<input type="checkbox"/> hip (without specifying) <input type="checkbox"/> left forearm <input type="checkbox"/> right forearm <input type="checkbox"/> forearm (without specifying)	<input type="checkbox"/> orally <input type="checkbox"/> intramuscular <input type="checkbox"/> intracutaneously <input type="checkbox"/> subcutaneously <input type="checkbox"/> other _____	
Best before /___/___/___/				

Kharkiv National Medical University

Department of Clinical Pharmacology and Internal Medicine Research protocol of drugs efficiency and safety (according to supervision) Study and research work

Student _____
(Full name, year, group, department)

Supervisor _____

POTOCOL

of investigation of medical agent pharmacodinamic _____

Patient (Full name, age, body mass) _____

Clinical diagnosis: main disease _____

Concominant disease _____

Date of investigation from c _____ to _____

1. Patient's therapy (present in prescriptions of 5 the most important drugs including the drug which was chosen for detail analysis)

2. Justification of the drug choice(international,trade names,chemical structure,particularities of drug introduction,pharmacokinetics, pharmacodinamics)

3. Expected therapeutic effect _____

4. Possible adverse effects _____

5. List the signs that will be used to monitor the therapeutic efficacy of drugs:

Before treatment

After treatment

Objective

- | | |
|----------|-------|
| A) _____ | _____ |
| B) _____ | _____ |
| C) _____ | _____ |
| D) _____ | _____ |
| E) _____ | _____ |

Physical

- | | |
|----------|-------|
| A) _____ | _____ |
| B) _____ | _____ |
| C) _____ | _____ |
| D) _____ | _____ |
| E) _____ | _____ |

Laboratory and instrumental

- | | |
|----------|-------|
| A) _____ | _____ |
| B) _____ | _____ |
| C) _____ | _____ |
| D) _____ | _____ |
| E) _____ | _____ |

6. List the symptoms that will control the side effects of drugs

Adverse effects

Presents of reaction in patient (yes, no)

Subjective

- | | |
|----------|-------|
| A) _____ | _____ |
| B) _____ | _____ |
| B) _____ | _____ |
| Г) _____ | _____ |
| Д) _____ | _____ |

Physical

- | | |
|----------|-------|
| A) _____ | _____ |
| B) _____ | _____ |
| C) _____ | _____ |
| D) _____ | _____ |
| E) _____ | _____ |

Laboratory and instrumental

- | | |
|----------|-------|
| A) _____ | _____ |
| B) _____ | _____ |
| C) _____ | _____ |
| D) _____ | _____ |
| E) _____ | _____ |

7. Evaluation of combination therapy (consider co-administration of a drug that was evaluated with other drugs from Section 1: pharmacokinetic, pharmacodynamic, pharmaceutical compatibility)

8. Conclusions and recommendations (efficiency of therapy, prognosis of further use, the possibility of replacing other drugs) _____

Investigation was made by_____ **Protocol was Checked by**_____

Clinical pharmacology
Self-study guide for 5 year English medium students
speciality “Dentistry”

Document compilers:

L.R. Bobronnikova

I.I.Kniazkova

V.V. Zlatkina

V.D. Nemtsova

Yu.N.Shaposhnikova

A.S. Shalimova

I.A. Ilchenko

Responsible for the issue : V.D. Nemtsova